Purchase of own shares LONDON, UK / ACCESSWIRE / October 1, 2024 / The Company announces that on 30 September 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
LONDON, UNITED KINGDOM / ACCESSWIRE / September 30, 2024 / Genflow (LSE:GENF) is pleased to announce its half year results for the six-month period ended 30 June 2024. Chairman's Statement It is with pleasure that I take this opportunity to update shareholders of Genflow Biosciences Plc ("Genflow" or the "Company") on the Company's performance during the first six months of 2024.
LONDON, UNITED KINGDOM / ACCESSWIRE / September 30, 2024 / The Company announces that on 27 September 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
LONDON, UNITED KINGDOM / ACCESSWIRE / September 27, 2024 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing therapies designed to transform blood disease treatment, whose shares are admitted to the equity shares (transition) category of the Official List, announces its unaudited interim results for the six-month period ended 30 June 2024. All financial amounts are stated in GBP British pounds unless otherwise indicated.
LONDON, UNITED KINGDOM / ACCESSWIRE / September 27, 2024 / The Company announces that on 26 September 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / Whole Genomic Sequencing and machine learning identifies key cancer genes associated with DNA proliferation and repair ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, is pleased to announce the publication of the 100th peer-reviewed journal article using the Parsortix® system for the isolation, harvest and analysis of CTCs. The journal article is published by researchers from a leading international referral centre for the treatment and study of cancer, the Fondazione IRCCS - Istituto Nazionale dei Tumori Di Milano (Italy).
LONDON, UK / ACCESSWIRE / September 26, 2024 / InterContinental Hotels Group PLC (the Company) The Company announces that on 25 September 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
Interim Results for the six months ended 30 June 2024 LARGE PHARMA STRATEGY IMPLEMENTED SUCCESSFULLY Three Large Pharma contracts secured each with substantial revenue potential Strategic decision post period end to focus resources on pharma services GUILDFORD, SURREY / ACCESSWIRE / September 26, 2024 / ANGLE plc ("ANGLE" or "the Company") ANGLE plc (AIM:AGL)(OTCQX:ANPCY), a world-leading liquid biopsy company with innovative circulating tumour cell (CTC) solutions for use in research, drug development and clinical oncology, today announces unaudited interim results for the six months ended 30 June 2024. Financial Highlights Revenues for the half-year of £1.0 million (H1 2023: £1.2 million) - sold order book of up to £1.9 million at period end Business re-shaped and streamlined with major focus on large pharma - cost savings of c.
Purchase of own shares LONDON, UK / ACCESSWIRE / September 25, 2024 / The Company announces that on 24 September 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
ISS and Glass Lewis Recommend i3 Energy Shareholders Vote FOR the Proposed Transaction with Gran Tierra Energy, Inc EASTLEIGH, UK / ACCESSWIRE / September 24, 2024 / I3 Energy is pleased to note that the two most influential independent proxy advisors, Institutional Shareholder Services (ISS), and Glass Lewis & Co. (Glass Lewis), have both recommended that shareholders vote FOR the proposed acquisition of i3 Energy by Gran Tierra Energy, Inc ("Gran Tierra") at the upcoming Court Meeting and General Meeting on 7 October. The Board of i3 Energy also reiterates its unanimous recommendation for shareholders to vote in favour of the proposed acquisition for the following reasons: 1.
LONDON, UNITED KINGDOM / ACCESSWIRE / September 24, 2024 / The Company announces that on 23 September 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.
LONDON, UNITED KINGDOM / ACCESSWIRE / September 23, 2024 / The Company announces that on 20 September 2024 it purchased the following number of its ordinary shares of 20340/399 pence each through Goldman Sachs International ("GSI") on the London Stock Exchange in accordance with the authority granted by shareholders at the Company's Annual General Meeting on 3 May 2024 (the "Purchase"). The Purchase was effected pursuant to instructions issued by the Company on 20 February 2024, as announced on 20 February 2024.